Increased serum fibroblast growth factor 21 levels are associated with adverse clinical outcomes after intracerebral hemorrhage

doi:10.3389/fnins.2023.1117057

科研成果详情

题名	Increased serum fibroblast growth factor 21 levels are associated with adverse clinical outcomes after intracerebral hemorrhage
作者	Chen, Keyang1,2,3; Huang, Wenting4; Wang, Jing2; Xu, Huiqin4; Ruan, Lixin 5; Li, Yongang 6; Wang, Zhen2; Wang, Xue2; Lin, Li2,3; Li, Xiaokun1,2,3
发表日期	2023-05-05
发表期刊	FRONTIERS IN NEUROSCIENCE 影响因子和分区
语种	英语
原始文献类型	Article
关键词	fibroblast growth factor-21 prognosis predictive value intracerebral hemorrhage enhancement
其他关键词	FGF21 ; SCORE
摘要	IntroductionIntracerebral hemorrhage (ICH) is the most prevalent cause of death. We sought to explore whether serum Fibroblast growth factor 21 (FGF21) is of substantial benefit in predicting poor prognosis in ICH patient. MethodsA prospective, multicenter cohort analysis of serum FGF21 levels in 418 ICH patients was carried out. At three months following ICH start, the primary endpoint was death or major disability, whereas the secondary endpoint was death. We investigated the association between serum FGF21 and clinical outcomes. We added FGF21 to the existing rating scale to assess whether it enhanced the prediction ability of the original model. Effectiveness was determined by calculating the C-statistic, net reclassification index (NRI), absolute integrated discrimination improvement (IDI) index. ResultsAmong 418 enrolled patients, 217 (51.9%) of the all subjects had death or significant disability. Compared with patients in the lowest quartile group, those in the first quartile group had higher risk of the primary outcome (Odds ratio, 2.73 [95%CI,1.42-5.26, p < 0.05]) and second outcome (Hazard ratio, 4.28 [95%CI,1.61-11.42, p < 0.001]). The integration of FGF21 into many current ICH scales improved the discrimination and calibration quality for the integrated discrimination index's prediction of main and secondary findings (all p < 0.05). ConclusionElevated serum FGF21 is associated with increased risks of adverse clinical outcomes at 3 months in ICH patients, suggesting FGF21 may be a valuable prognostic factor.
资助项目	Medical Health Science and Technology Project of Zhejiang Provincial Health Commission[2023KY307,2023KY905,WKJ-ZJ-2130];National Natural Science Foundation of China[81971180];
出版者	FRONTIERS MEDIA SA
ISSN	1662-453X
EISSN	1662-453X
卷号	17
DOI	10.3389/fnins.2023.1117057
页数	8
WOS类目	Neurosciences
WOS研究方向	Neurosciences & Neurology
WOS记录号	WOS:000989238100001
收录类别	SCIE ; PUBMED ; SCOPUS
URL	查看原文
PubMed ID	37214383
SCOPUSEID	2-s2.0-85159877255
通讯作者地址	[Li, Xiaokun]Department of Neurology,The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University,Wenzhou,China ; [Lin, Li]School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou,China
Scopus学科分类	Neuroscience (all)
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/180084
专题	第二临床医学院、附属第二医院、育英儿童医院药学院（分析测试中心）附属第二医院附属第一医院第二临床医学院、附属第二医院、育英儿童医院_神经病学卓越中心_国际生长因子研究院
通讯作者	Lin, Li; Li, Xiaokun
作者单位	1.Department of Neurology,The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University,Wenzhou,China; 2.School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou,China; 3.Research Units of Clinical Translation of Cell Growth Factors and Diseases Research,Chinese Academy of Medical Science,Wenzhou Medical University,Wenzhou,China; 4.Department of Neurology,The First Affiliated Hospital Hospital of Wenzhou Medical University,Wenzhou,China; 5.The People’s Hospital of Pingyang,Wenzhou,China; 6.The First People’s Hospital of Wenling,Taizhou,China
第一作者单位	第二临床医学院，附属第二医院、育英儿童医院; 附属第二医院; 药学院（分析测试中心）; 温州医科大学
通讯作者单位	第二临床医学院，附属第二医院、育英儿童医院; 附属第二医院; 药学院（分析测试中心）
第一作者的第一单位	第二临床医学院，附属第二医院、育英儿童医院
推荐引用方式 GB/T 7714	Chen, Keyang,Huang, Wenting,Wang, Jing,et al. Increased serum fibroblast growth factor 21 levels are associated with adverse clinical outcomes after intracerebral hemorrhage[J]. FRONTIERS IN NEUROSCIENCE,2023,17.
APA	Chen, Keyang., Huang, Wenting., Wang, Jing., Xu, Huiqin., Ruan, Lixin., ... & Li, Xiaokun. (2023). Increased serum fibroblast growth factor 21 levels are associated with adverse clinical outcomes after intracerebral hemorrhage. FRONTIERS IN NEUROSCIENCE, 17.
MLA	Chen, Keyang,et al."Increased serum fibroblast growth factor 21 levels are associated with adverse clinical outcomes after intracerebral hemorrhage".FRONTIERS IN NEUROSCIENCE 17(2023).